SAB Biotherapeutics, Inc. (SABS) Stock Profile — Insider Trades & Financials

Net Income-$16.9M

EPS$-0.33

Market Cap$190.0M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Samuel Reich

CEO & Executive Director

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Founded: 2014
Employees: 86
Headquarters: Miami Beach, Florida, United States
Website

⚡

Core Efficiency

ROE?

-11.13%

ROA?

-9.76%

D/E Ratio?

0.14

📊

Profitability Ratios

Current Ratio?

9.46

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 29, 2026 (in 142 days)

Annual Report (10-K) — Based on filing pattern

Aug 29, 2026

Predicted10-K

Mar 9, 2026

10-KQ4 20257d after period end

Mar 9, 2026

10-KFY 202568d after period end

Nov 14, 2025

10-QQ3 20254d after period end

Aug 7, 2025

10-QQ2 20256d after period end

May 9, 2025

10-QQ1 20257d after period end

Mar 31, 2025

10-KQ4 202410d after period end

Mar 31, 2025

10-KFY 202590d after period end

Nov 6, 2024

10-QQ3 20245d after period end

Loading company sections...

SAB Biotherapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness